ReviewHeart failure reviews2023
Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction.
Review in Heart failure reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Improvement of Hemodynamics and Quality of Life Before and After Interatrial Shunt Devices Implantation for Chronic Heart Failure: A Systematic Review and Meta-analysis.Current cardiology reviews · 2025Pooled it
- Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review.Journal of Brown hospital medicine · 2026Review
- Greater Splanchnic Nerve Ablation in Heart Failure with Preserved Ejection Fraction: a Mini-Narrative Review of Emerging Evidence.European journal of medical research · 2025Review
- Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances.Cardiorenal medicine · 2025Review
- Progress of echocardiography in the evaluation of left atrial function in patients with heart failure with preserved ejection fraction: a narrative review.Quantitative imaging in medicine and surgery · 2024Review
- Left Atrial Hemodynamics and Clinical Utility in Heart Failure.Reviews in cardiovascular medicine · 2024Review
- Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment.Reviews in cardiovascular medicine · 2024Review
- Short-term study of atrial shunt and improvement of functional mitral regurgitation.Journal of cardiothoracic surgery · 2023Article
- Novel Device Therapies for Heart Failure.Journal of cardiovascular development and disease · 2023Article
- Medical Management and Device-Based Therapies in Chronic Heart Failure.Journal of the Society for Cardiovascular Angiography & InterventionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction is responsible for half of all heart failure and confers substantial morbidity and mortality, and yet to date, there have been no effective pharmacologic interventions. Although the pathophysiology is complex, the primary aetiology of exercise intolerance is due to an elevated left atrial pressure, particularly with exercise. In this context, device-based therapy has become a focus. Several companies have developed techniques to percutaneously create an iatrogenic left to right shunt at the atrial level, thereby reducing left atrial pressure and reducing transmitted pressures to the pulmonary circulation and reducing pulmonary congestion. In this review, we explore the pathophysiology, evidence base, benefits, and considerations of these devices and their place in the therapeutic landscape of heart failure with preserved ejection fraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.